NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) announced today that the latest public data on its Aganocide^® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida.

NovaBay's Aganocide compounds are first-in-class anti-infectives being developed for the treatment and prevention of antibiotic-resistant infections. NovaBay and Alcon, Inc., the world's leading eye care company, have a licensing and research collaboration agreement for the use of NovaBay's Aganocide compounds in the eye, ear and sinus, and for contact lens care.

The following abstracts will be presented:

 "In vitro Microbicidal Activity in Tears of N,N-dichloro-2,2-dimethyltaurine (NVC-422, AL-46383A), a Novel Topical Ophthalmic Agent,"

• Monday, May 3, from 1:45 p.m. to 3:30 p.m.
• Abstract Authors: Dr. Kathryn Najafi, founder and medical director of the Eye Institute of Marin and a NovaBay advisor; Dr. Stephen Wilmarth, NovaBay advisor and a founding member of Medical Vision Technology; and David Stroman, Ph.D., and Masood Chowhan, Ph.D., of Alcon Laboratories, et. al.

"In vitro Evaluation of N,N-dichloro-2,2-dimethyltaurine (AL-46383A) as an Antiviral Agent Against Adenovirus and HSV-1,"

• Monday, May 3, from 3:45 p.m. to 5:30 p.m.
• Abstract Authors: Eric G. Romanowski, Kathleen Yates, and Dr. Y. Jerold Gordon of the Charles T. Campbell Lab at the University of Pittsburgh; and David Stroman, Ph.D. of Alcon Laboratories., et. al.

"Topical N,N-dichloro-2,2-dimethyltaurine (AL-46383A) Inhibits Adenovirus Replication in the Ocular Ad5/NZW Rabbit Replication Model,"

• Thursday, May 6, from 2:45 p.m. to 3 p.m.
• Abstract Authors: Dr. Y. Jerold Gordon, Kathleen A. Yates and Eric G. Romanowski of the Charles T. Campbell Lab at the University of Pittsburgh et. al. and David Stroman, Ph.D., of Alcon Laboratories

Abstracts of the presentations may be accessed at www.arvo.org.

NVC-422, or AL-46383A, is a stable compound based on the chemical structures of N-chlorotaurine (NCT) and N,N-dichlorotaurine, which are naturally occurring antimicrobial agents produced by the body's white blood cells to fight invasive pathogens.

Alcon is conducting a Phase 2 clinical trial of this compound for the treatment of viral conjunctivitis, a form of "pink eye". The randomized, placebo-controlled trial is enrolling approximately 250 patients at more than 30 medical centers in the United States and worldwide. It is designed to determine the safety and efficacy of NVC-422 or AL-46383A.